Mounjaro Doses: What to Expect at Each Stage of Treatment
Mounjaro (tirzepatide) is started low and increased slowly — beginning at 2.5 mg once weekly and stepping up in 2.5 mg increments no sooner than every four weeks, up to a maximum of 15 mg. The starting dose is an adaptation dose, not a treatment dose, and the highest dose is not the goal: the aim is the lowest dose that controls appetite and sustains weight loss with acceptable side effects. This guide walks through each stage, the escalation schedule, side effects, missed doses, and what the SURMOUNT trial data show. [1]
What Is the Mounjaro Dosage Schedule?
Mounjaro (tirzepatide) follows a structured dose-escalation schedule rather than starting at a full therapeutic dose. Treatment begins at 2.5 mg once weekly for four weeks, then rises in 2.5 mg increments — 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg — with each dose held for at least four weeks before the next increase, and only when clinically appropriate. This design improves tolerability while supporting sustainable long-term weight management.
Starting Mounjaro can feel both exciting and overwhelming, especially because treatment involves gradual dose increases over several months. Understanding the schedule helps set realistic expectations and navigate each stage with confidence. Mounjaro is a once-weekly injectable containing tirzepatide, a dual-action agent that simultaneously activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors — hormones involved in appetite regulation, satiety, insulin secretion and energy balance. By targeting both pathways, it reduces hunger, controls cravings and supports clinically significant weight loss alongside healthy lifestyle changes. [3, 17]
At Karespot, Internal Medicine specialists and Endocrinologists provide personalised support at every stage of the Mounjaro journey — from eligibility assessment and dose selection to escalation monitoring and long-term progress reviews.
What Is Mounjaro, and Why Is It Different?
Mounjaro (tirzepatide) is a once-weekly prescription injection approved to improve blood sugar control in type 2 diabetes and to support weight management in eligible adults with overweight or obesity. What sets it apart is dual GIP/GLP-1 receptor agonism — it enhances satiety and reduces calorie intake through two complementary hormonal pathways rather than one, which is why trial weight-loss results are among the largest reported for any weight-management medicine.
In the landmark SURMOUNT-1 randomised controlled trial of 2,539 adults with obesity, tirzepatide produced mean body-weight reductions of 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg after 72 weeks, versus 3.1% with placebo. [2] Among patients with type 2 diabetes in SURMOUNT-2, mean weight loss reached 13.4% with 10 mg and 15.7% with 15 mg. [10] In a head-to-head comparison with semaglutide, the SURPASS-2 trial showed superior HbA1c reduction and significantly greater weight loss with tirzepatide at equivalent weekly dosing. [18]
Key benefits of Mounjaro
- Significant and clinically validated weight loss
- Reduced appetite and food cravings
- Increased and prolonged feelings of fullness
- Improved blood sugar regulation
- Better portion control and eating behaviour
- Support for long-term weight-management goals
Before prescribing Mounjaro, Karespot's specialists conduct a comprehensive assessment covering BMI, medical history, metabolic health, comorbidities and previous weight-management attempts — ensuring tirzepatide is recommended only for patients likely to benefit and able to use it safely.
How Do You Take Mounjaro?
Mounjaro is a once-weekly subcutaneous injection given with a pre-filled pen into the abdomen, thigh or upper arm, ideally on the same day each week. It can be taken at any time of day, with or without food. Rotate injection sites to reduce skin irritation, and if the injection day must change, keep at least 72 hours (3 days) between doses.
Mounjaro works best when combined with a balanced diet, regular physical activity, adequate sleep and ongoing medical supervision. [11]
Key administration tips
- Take Mounjaro once weekly on the same day each week
- Rotate injection sites: abdomen, thigh or upper arm
- Can be taken with or without food, at any time of day
- Follow the prescribed dose-escalation schedule precisely
- Never adjust your dose without medical advice
- Attend all scheduled follow-up appointments
Many patients are initially anxious about self-injection. Karespot's clinical team provides detailed guidance on injection technique, site rotation, dose scheduling and missed-dose management so patients feel confident from day one.
What Strengths Does Mounjaro Come In?
Mounjaro comes in six once-weekly strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg. These support gradual escalation and safe progression. The goal is not to reach 15 mg but to find the lowest effective maintenance dose — many patients achieve meaningful, lasting results at 5 mg or 10 mg without going higher.
All six strengths are delivered as a subcutaneous injection and exist specifically to enable the step-wise escalation protocol while improving tolerability. [1, 9]
| Mounjaro strength | Typical clinical purpose |
|---|---|
| 2.5 mg | Treatment initiation and tolerability assessment |
| 5 mg | First therapeutic dose; appetite and weight-management support |
| 7.5 mg | Intermediate escalation when additional support is needed |
| 10 mg | Enhanced appetite suppression and weight-loss support |
| 12.5 mg | Higher escalation dose when clinically appropriate |
| 15 mg | Maximum approved maintenance dose |
A common misconception is that 15 mg is the "target" dose. At Karespot, specialists assess each patient's weight-loss progress, appetite control, metabolic health and tolerability before recommending any escalation — many patients achieve excellent long-term results without ever reaching the highest available dose.
What Is the Starting Dose for Mounjaro?
The recommended starting dose is 2.5 mg once weekly for the first four weeks. This is an initiation dose, not a therapeutic weight-loss dose — its purpose is to let the body adjust to tirzepatide and reduce gastrointestinal side effects such as nausea, vomiting, diarrhoea and constipation. After four weeks, most patients move to 5 mg if treatment is well tolerated.
Some patients notice early appetite changes or mild weight loss during this phase, but significant effects are more commonly seen after progressing to therapeutic doses of 5 mg and above. A lower starting dose is not a sign the medication is not working. [1, 5]
| Treatment period | Weekly dose | Purpose |
|---|---|---|
| Weeks 1–4 | 2.5 mg | Treatment initiation and tolerability assessment |
| Weeks 5–8 | 5 mg | First therapeutic dose; appetite and weight-loss support |
| Weeks 9+ (if required) | 7.5 mg–15 mg | Progressive escalation under medical supervision |
A frequent misconception is that a lower starting dose means the medication is not working. Karespot's team clearly explains that 2.5 mg is an adaptation dose, not a therapeutic one — patients who understand this are better prepared for the escalation journey ahead.
What Does the Mounjaro Escalation Schedule Look Like?
Mounjaro escalates gradually from 2.5 mg toward a maximum of 15 mg over roughly 20 weeks. Doses rise in 2.5 mg increments, and patients stay on each dose for at least four weeks before any further increase — and only when clinically appropriate. Not every patient needs to reach 15 mg.
The schedule below is a typical template; the real pace is individual. Some patients hold a dose longer if side effects need settling, while others move up when results plateau and tolerability is good. [1, 8]
| Weeks of treatment | Mounjaro dose |
|---|---|
| Weeks 1–4 | 2.5 mg once weekly |
| Weeks 5–8 | 5 mg once weekly |
| Weeks 9–12 | 7.5 mg once weekly (if required) |
| Weeks 13–16 | 10 mg once weekly (if required) |
| Weeks 17–20 | 12.5 mg once weekly (if required) |
| Week 21 onwards | 15 mg once weekly (if appropriate) |
1–4
5–8
9–12
13–16
17–20
Max
Why is Mounjaro increased gradually?
- Improves gastrointestinal tolerability by letting the digestive system adapt
- Reduces the severity and frequency of nausea, vomiting and bloating
- Allows appetite regulation to develop progressively
- Enables clinicians to assess individual response at each dose stage
- Supports long-term adherence and reduces early discontinuation
Karespot's specialists monitor patients closely throughout escalation. Those with significant side effects may hold the current dose longer before increasing; those who tolerate treatment well but plateau may be guided to the next stage. This flexible, patient-centred approach replaces a rigid one-size-fits-all timeline.
Stage 1: Starting Mounjaro at 2.5 mg
The first four weeks at 2.5 mg are an adaptation phase, not a weight-loss phase. The digestive system adjusts to tirzepatide's effects on appetite hormones, gastric emptying and insulin secretion. Some patients notice reduced appetite or mild early weight loss; others see little change on the scale — both are normal at this stage.
What you may notice at 2.5 mg
- Reduced appetite and fewer food cravings
- Feeling fuller with smaller meal portions
- Less frequent snacking between meals
- Mild early weight loss (varies between individuals)
- Greater awareness of hunger and fullness cues
Common side effects at 2.5 mg
- Nausea — most common; usually mild and transient
- Constipation or diarrhoea — digestive system adapting to slower gastric emptying
- Bloating or indigestion — related to appetite-hormone changes
- Mild abdominal discomfort — typically resolves within days
Karespot's team helps patients understand that the 2.5 mg dose is intentionally modest. During follow-up, specialists monitor appetite changes, side-effect severity and adherence to decide whether the patient is ready to progress to 5 mg.
Stage 2: Moving to Mounjaro 5 mg
After four weeks on 2.5 mg, most patients progress to 5 mg — the first true therapeutic dose. Many notice stronger appetite suppression, reduced cravings, better portion control and more consistent weight loss. In SURMOUNT-1, 5 mg tirzepatide produced a mean body-weight reduction of 15.0% at 72 weeks.
Temporary gastrointestinal side effects may occur with this first increase as the body adapts; they are usually mild and resolve within days to weeks. For many patients, 5 mg strikes an effective balance between appetite control and tolerability, with no further escalation required. [2, 9]
The 2.5 mg to 5 mg transition is a pivotal milestone. Karespot's team assesses appetite patterns, eating behaviours, side effects and overall response before considering further escalation — ensuring patients progress at the right pace for their metabolism and lifestyle.
Stages 3 & 4: Escalating to 7.5 mg and 10 mg
For patients who need more support beyond 5 mg, stepping up to 7.5 mg and then 10 mg once weekly may be appropriate. These doses provide stronger appetite suppression and help maintain momentum when progress slows or hunger returns. In SURMOUNT-1, 10 mg produced a mean weight loss of 19.5% over 72 weeks — significantly greater than the 5 mg response.
A weight plateau on its own is not automatically an indication to increase the dose; other contributing factors are considered first. [2]
Before recommending escalation to 7.5 mg or 10 mg, Karespot's specialists review appetite control, dietary patterns, physical activity, adherence and metabolic markers — not just the number on the scale.
Escalating to Higher Doses (12.5 mg & 15 mg) and Maintenance
The final escalation stages, 12.5 mg and 15 mg once weekly, are the highest approved doses. In SURMOUNT-1, 15 mg achieved the greatest mean weight loss (20.9% at 72 weeks); SURMOUNT-2 showed 15.7% in patients with type 2 diabetes. But not everyone needs these higher doses — many achieve sustained results on 5 mg or 10 mg. Maintenance aims to preserve results at the lowest effective dose.
Evidence from SURMOUNT-4 confirms that discontinuing tirzepatide leads to significant weight regain, underscoring the importance of continued treatment. [1, 16]
Important considerations at maintenance
- Higher doses are not necessary for every patient
- Side effects may increase at higher dose levels — regular monitoring is essential
- Long-term success depends on both medication and sustained lifestyle changes
- Dose can be adjusted over time based on ongoing clinical review
- Regular medical assessments support safe, effective maintenance therapy
Never escalate, skip or stop your dose on your own, and never combine Mounjaro with another GLP-1 or GIP/GLP-1 medicine. Dose decisions belong with your prescriber.
At Karespot, the focus during maintenance is identifying the lowest effective dose that supports sustainable outcomes. Specialists review weight trends, appetite control, tolerability and long-term goals, and adjust based on evidence, not assumptions.
Common Side Effects During Mounjaro Dose Escalation
The most frequent Mounjaro side effects during escalation are gastrointestinal: nausea, constipation, diarrhoea, bloating and indigestion. They are generally mild to moderate, most noticeable in the first few days after a dose increase, and tend to resolve as the body adapts. Dietary adjustments significantly improve tolerability.
| Side effect | Why it may occur | Typical duration |
|---|---|---|
| Nausea | Changes in gastric emptying and appetite-hormone signalling | Days to weeks; often transient |
| Constipation | Slowed gastrointestinal motility | Resolves with dietary adjustments |
| Diarrhoea | Digestive system adapting to tirzepatide | Usually short-lived |
| Bloating | Delayed stomach emptying | Improves as the dose stabilises |
| Indigestion | Adjustment to treatment | Typically transient |
| Abdominal discomfort | Temporary digestive changes | Usually within the first week of a new dose |
Evidence-based tips for managing side effects
- Eat smaller, more frequent meals and avoid large portions
- Prioritise protein- and fibre-rich foods; limit high-fat or ultra-processed meals
- Stay well hydrated throughout the day
- Eat slowly and stop when comfortably satisfied
- Follow the prescribed dosing schedule without self-adjusting doses
Contact your provider if you experience persistent or severe nausea, repeated vomiting, difficulty staying hydrated, significant abdominal pain, or side effects that materially affect your ability to eat or your daily activities. See also: Managing Mounjaro Side Effects. [1]
Karespot's team monitors side effects throughout the entire escalation process. When symptoms are significant, they may recommend staying at the current dose longer, reviewing dietary habits or adjusting hydration — rather than automatically proceeding to the next dose level.
What Happens If I Miss a Mounjaro Dose?
Missing one dose does not require restarting treatment. If you remember within 4 days (96 hours), take the missed dose as soon as possible and continue your regular weekly schedule. If more than 4 days have passed, skip it and take your next injection on the usual scheduled day. Never take two doses within 3 days (72 hours) of each other.
| Time since missed dose | Recommended action |
|---|---|
| Within 4 days (96 hours) | Take the missed dose as soon as possible and continue your regular weekly schedule |
| More than 4 days (96 hours) | Skip the missed dose and take your next injection on the usual scheduled day |
(4 days)
(4 days)
Important reminders
- Never take two doses within 3 days (72 hours) of each other
- Do not take an extra dose to make up for a missed injection
- Set a weekly phone or calendar reminder to avoid future missed doses
- Contact your healthcare provider if you miss multiple consecutive doses
Missed doses are among the most common concerns raised at follow-up. Karespot's specialists advise based on your current dose stage and escalation progress, and may recommend a modified approach if several consecutive doses have been missed.
Weight-Loss Expectations Throughout Mounjaro Treatment
The strongest evidence comes from the SURMOUNT programme. In SURMOUNT-1 (2,539 adults with obesity, without type 2 diabetes), tirzepatide produced mean weight reductions of 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg after 72 weeks, versus 3.1% with placebo. Results build gradually, vary between individuals, and are rarely linear — temporary plateaus are a normal, expected part of the journey.
In SURMOUNT-2, which enrolled adults with type 2 diabetes, mean weight loss reached 13.4% with 10 mg and 15.7% with 15 mg. SURMOUNT-3 showed even greater reductions in patients who completed an intensive lifestyle run-in before starting tirzepatide, while SURMOUNT-4 confirmed sustained weight maintenance with continued treatment versus placebo. [10, 15, 16]
What to expect at each phase
Weight loss is rarely linear — temporary plateaus are normal and expected. Progress shows up in appetite control, waist circumference, metabolic markers and how clothes fit, not only the number on the scale.
Setting realistic expectations is one of the most impactful parts of Karespot's approach. Follow-ups evaluate appetite control, eating behaviour, waist circumference, metabolic markers and overall wellbeing — helping patients recognise meaningful progress even during plateaus.
Tips for Navigating Your Mounjaro Journey Successfully
Long-term success combines medication with sustained lifestyle habits and consistent medical support. Take your injection on the same day each week, use reminders to avoid missed doses, never adjust your dose without guidance, and keep up with follow-up appointments so your plan can be tailored as you progress.
Stay consistent with weekly dosing
- Take your injection on the same day each week — consistency is clinically important
- Use phone reminders, medication apps or calendar alerts to avoid missed doses
- Never adjust your dose without guidance from your healthcare provider
Starting Mounjaro, or unsure what dose is right for you?
Every Karespot patient is assessed and supervised by a registered MBBS + MD (Internal Medicine) prescriber, with a dietician, clinical psychologist and health coach alongside. Dose selection, escalation, side effects and progress reviews are managed at every stage.
Check Your Eligibility → Explore more guides on Kare Hub →Frequently Asked Questions About Mounjaro Doses
How long do you stay on each Mounjaro dose?
Do I have to increase my Mounjaro dose every month?
What is the best maintenance dose of Mounjaro?
How much weight can I lose on Mounjaro?
What happens if I miss a Mounjaro dose?
What are the most common side effects when increasing Mounjaro doses?
Is it normal to stop losing weight on Mounjaro?
Can I switch from Mounjaro to Wegovy?
How quickly does Mounjaro start working?
What should I do if a dose increase feels too strong?
Eli Lilly and Company. Mounjaro (tirzepatide) Prescribing Information. Revised 2025.
pi.lilly.com — Mounjaro Prescribing InformationJastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216.
doi.org/10.1056/NEJMoa2206038Farzam K, Patel P. Tirzepatide. StatPearls. StatPearls Publishing; 2024.
ncbi.nlm.nih.gov/books/NBK585056Mody R, et al. Characteristics and Dosing Patterns of Tirzepatide Users with Type 2 Diabetes. Diabetes Ther. 2025;16:357–372.
pmc.ncbi.nlm.nih.gov — PMC11794899U.S. Food and Drug Administration. Mounjaro (tirzepatide) Prescribing Information. 2022.
accessdata.fda.gov — Mounjaro LabelEli Lilly and Company. Mounjaro KwikPen Strengths and Doses. Lilly Canada.
lilly.com/en-CA — Mounjaro KwikPenMedical News Today. Why do you have to increase Mounjaro dose? Accessed June 2026.
medicalnewstoday.com — increase Mounjaro doseDrugs.com. Mounjaro: Uses, Dosage, Side Effects and Warnings. Accessed June 2026.
drugs.com/mounjaro.htmlHealthline. Mounjaro Dosage Guide. Accessed June 2026.
healthline.com — Mounjaro DosageGarvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613–626.
doi.org/10.1016/S0140-6736(23)01200-XNational Health Service (NHS). Tirzepatide (Mounjaro). Accessed June 2026.
nhs.uk — Tirzepatide (Mounjaro)Karespot. Managing Mounjaro Side Effects: A Clinical Guide. Kare Hub, 2026.
karespot.in — Managing Mounjaro Side EffectsKarespot. Switching from Semaglutide to Mounjaro: A Safe Transition Guide. Kare Hub, 2026.
karespot.in — Switching Semaglutide to MounjaroKarespot. Silencing Food Noise: How Medical Weight Loss Treatment Can Help. Kare Hub, 2026.
karespot.in — Silencing Food NoiseWadden TA, et al. Tirzepatide After Intensive Lifestyle Intervention in Adults With Overweight or Obesity (SURMOUNT-3). Nat Med. 2023;29(11):2713–2723.
doi.org/10.1038/s41591-023-02610-2Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA. 2024;331(1):38–48.
doi.org/10.1001/jama.2023.24945Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(24):e140532.
doi.org/10.1172/jci.insight.140532Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503–515.
doi.org/10.1056/NEJMoa2107519European Medicines Agency. Mounjaro (tirzepatide): European Public Assessment Report (EPAR). EMA/428037/2023. 2023.
ema.europa.eu — Mounjaro EPARNational Institute for Health and Care Excellence. Tirzepatide for managing overweight and obesity. Technology appraisal guidance TA1026. September 2024.
nice.org.uk/guidance/ta1026Dr. Prakrati Garg is a Research Associate and published researcher in Biotechnology at Shoolini University, and Content Strategist at Karespot. With deep expertise in herbal drug development, nanotechnology and advanced drug delivery systems, she brings a rigorous scientific lens to Karespot's health and wellness content.
Dr. Sana Umar is an Assistant Professor at Doon Medical College and Medical Reviewer at Karespot, responsible for ensuring all clinical content meets accuracy, safety and evidence-based standards. A Clinical Pathologist with FRCP credentials and NMC registration (Reg. 8506), she reviews articles for alignment with current prescribing guidelines and international best practices in GLP-1 therapy and weight-management medicine.
Weight loss can feel like a lonely road. At Karespot, we believe you should never have to walk it alone.
Karespot is a telehealth platform that connects patients across India with a team of MBBS + MD (Internal Medicine) specialists and Endocrinologists who provide personalised, medically supervised care. We believe medication is a tool, not the answer alone. Real, lasting change comes from building the habits and lifestyle that carry you forward long after treatment ends.
Every Karespot patient is supported by a holistic team: a doctor who understands your metabolic health, a registered dietician who adapts your nutrition to your real life, a clinical psychologist who helps you understand your relationship with food, and a lifestyle health coach who helps you build the daily habits that last.
Delhi & NCR: New Delhi, Noida, Gurugram, Faridabad, Ghaziabad
Uttarakhand: Dehradun, Haridwar, Roorkee, Haldwani, Rudrapur, Rishikesh, Nainital, Kotdwar
Uttar Pradesh: Lucknow, Kanpur, Agra, Varanasi, Prayagraj, Meerut, Gorakhpur, Aligarh, Bareilly
Maharashtra: Mumbai, Pune, Nagpur, Nashik, Thane, Navi Mumbai, Aurangabad (Chhatrapati Sambhajinagar)
Karnataka: Bengaluru, Mysuru, Mangaluru, Hubballi-Dharwad, Belagavi
Telangana: Hyderabad, Warangal, Nizamabad, Karimnagar
Punjab & Chandigarh: Amritsar, Ludhiana, Jalandhar, Patiala, Chandigarh, Mohali
Other Cities: Chennai, Kolkata, Ahmedabad, Jaipur, Surat, Kochi, Indore, Coimbatore, Bhopal, Visakhapatnam, Thiruvananthapuram
Medical Disclaimer: This article is for general informational purposes only and does not replace personalised medical advice. Mounjaro (tirzepatide) is a prescription medicine that must be prescribed and supervised by a qualified Internal Medicine specialist or Endocrinologist. Always consult your Karespot doctor before starting, stopping or adjusting any treatment.
